Role of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction

Mechanism and Indications

The European Society of Cardiology recommends sacubitril/valsartan as a replacement for ACE inhibitors to further reduce the risk of heart failure hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker, and a mineralocorticoid receptor antagonist 1, 2, 3

Clinical Benefits in HFrEF

Sacubitril/valsartan reduces the risk of heart failure hospitalization and death compared to ACE inhibitors in patients with symptomatic HFrEF despite optimal medical therapy 1, 2, 3

Placement in Treatment Algorithm for HFrEF

The European Heart Society recommends a treatment algorithm for HFrEF, starting with first-line therapy of ACE inhibitor + beta-blocker 1, 2, 3
The European Heart Society recommends adding a mineralocorticoid receptor antagonist (MRA) as second-line therapy if the patient remains symptomatic 1, 2, 3
The European Heart Society recommends replacing ACE inhibitor with sacubitril/valsartan as third-line therapy if the patient remains symptomatic despite optimal therapy with the above medications 1, 2, 3

Potential Drug Interactions

Sacubitril/valsartan may increase levels of statins that are substrates of OATP1B1, OATP1B3, OAT1, and OAT3 transporters, according to the American Heart Association 4, 5
The American Heart Association recommends considering lower doses of atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin when used in combination with sacubitril/valsartan 5

Emerging Evidence in Other HF Populations

The American College of Cardiology suggests that sacubitril/valsartan may provide benefits in heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%) 6

Role of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction

Indications and Clinical Benefits

The European Society of Cardiology recommends sacubitril/valsartan as a replacement for ACE inhibitors or ARBs in patients with heart failure with reduced ejection fraction (HFrEF) to reduce the risk of heart failure hospitalization and death, with a strong recommendation based on high-quality evidence 7
Sacubitril/valsartan is indicated for patients with symptomatic HFrEF who remain symptomatic despite optimal medical therapy with an ACE inhibitor/ARB, beta-blocker, and mineralocorticoid receptor antagonist, with a high level of evidence supporting its use 7

Placement in Treatment Algorithm for HFrEF

The European Heart Journal suggests that sacubitril/valsartan can be considered as third-line therapy for patients with HFrEF who remain symptomatic despite optimal therapy with ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, with a moderate level of evidence supporting its use 7, 8

Practical Considerations

The European Heart Journal notes that diuretic doses may need to be reduced due to enhanced natriuresis when using sacubitril/valsartan, with a low level of evidence supporting this recommendation 7
The European Heart Journal also mentions that cost and insurance coverage may be potential barriers to the use of sacubitril/valsartan, with a low level of evidence supporting this statement 8

Entresto Therapy in Heart Failure with Reduced Ejection Fraction

Indications and Administration

The American College of Cardiology recommends Entresto for patients with heart failure with reduced ejection fraction (HFrEF) as a replacement for ACE inhibitors or ARBs, to be administered in conjunction with other guideline-directed medical therapy (GDMT) for heart failure 9
Entresto is indicated for patients with HFrEF (EF ≤40%) with NYHA class II-IV symptoms 9

Clinical Benefits and Safety

Entresto has demonstrated significant improvements in cardiac remodeling, with studies showing increased left ventricular ejection fraction and decreased left ventricular volumes 9
When transitioning from an ACE inhibitor to Entresto, a 36-hour washout period must be strictly observed to avoid angioedema 9
No washout period is required when switching from an ARB to Entresto 9

Practical Implementation and Dosing

Initial dosing of Entresto depends on prior therapy, with patients on high-dose ACE inhibitors starting with 49/51 mg twice daily, and those on low/medium-dose ACE inhibitors or ARBs, or treatment-naïve patients, starting with 24/26 mg twice daily 9, 10
For patients with severe renal impairment, moderate hepatic impairment, or elderly patients (≥75 years), start with the lowest dose (24/26 mg twice daily) 9
In patients with low blood pressure, consider starting with the lowest dose and up-titrating slowly with small increments 10

Special Considerations

Symptomatic hypotension in chronic HFrEF can usually be managed through patient education and counseling without reducing HF pharmacotherapy 10
Monitor renal function and electrolytes, particularly when used with aldosterone antagonists 11
History of angioedema related to previous ACE inhibitor or ARB therapy is a precaution for Entresto use 9
Severe renal impairment requires dose adjustment of Entresto, not avoidance 9
Concomitant use with ACE inhibitors is contraindicated, requiring a 36-hour washout period 9

Sacubitril/Valsartan Treatment for Heart Failure with Reduced Ejection Fraction

Initial Dosing Recommendations

The American College of Cardiology recommends starting sacubitril/valsartan at 49/51 mg twice daily for patients previously on high-dose ACE inhibitors, 24/26 mg twice daily for patients on low/medium-dose ACE inhibitors or ARBs, and 24/26 mg twice daily for patients with no prior ACE inhibitor/ARB exposure (de novo) 12
For patients with severe renal impairment, moderate hepatic impairment, or elderly patients (≥75 years), the American College of Cardiology recommends starting with 24/26 mg twice daily 12

Titration Schedule

The European Society of Cardiology suggests doubling the dose every 2-4 weeks as tolerated to reach the target dose of 97/103 mg twice daily, which has been shown to provide maximum mortality benefit in clinical trials 13

Important Precautions

The American College of Cardiology advises monitoring for symptomatic hypotension, especially during initiation and dose titration, and considers reducing diuretic doses in non-congested patients to mitigate hypotensive effects 12

Special Considerations

The American College of Cardiology recommends careful administration and follow-up in patients with borderline blood pressure (systolic BP ≤100 mm Hg) 12
The European Society of Cardiology suggests that for patients experiencing hypotension, consider temporarily reducing the dose rather than discontinuing therapy completely, as 40% of patients who required temporary dose reduction were subsequently restored to target doses 13
Sacubitril/valsartan remains indicated in patients with NYHA class IV symptoms, though data in this population are limited, according to the American College of Cardiology 12

Common Pitfalls to Avoid

The European Society of Cardiology warns against failure to titrate to target doses due to asymptomatic hypotension or mild laboratory changes, and against permanent dose reductions when temporary reductions with subsequent re-titration would be more appropriate 13
The European Society of Cardiology also advises against treating heart failure less aggressively than other life-threatening conditions like cancer, despite similar mortality risks, and against believing that medium-range doses provide most of the benefits of target doses 14

Dosage and Administration of Sacubitril/Valsartan for Heart Failure with Reduced Ejection Fraction

Special Considerations

The American College of Cardiology recommends that for patients with moderate hepatic impairment (Child-Pugh B), the starting dose of sacubitril/valsartan should be 24/26 mg twice daily 15
Recent data from the American College of Cardiology support direct initiation of sacubitril/valsartan without a pretreatment period with ACEIs or ARBs as a safe and effective strategy 15

Sacubitril/Valsartan Therapy for Heart Failure with Reduced Ejection Fraction

Placement in Treatment Algorithm

The European Society of Cardiology recommends ACE inhibitor + beta-blocker as first-line therapy for patients with heart failure with reduced ejection fraction (HFrEF) 16
The European Society of Cardiology suggests adding a mineralocorticoid receptor antagonist (MRA) as second-line therapy if the patient remains symptomatic despite optimal first-line therapy 16
The European Society of Cardiology recommends replacing ACE inhibitor/ARB with sacubitril/valsartan as third-line therapy if the patient remains symptomatic despite optimal therapy with the above medications 16, 17
The European Society of Cardiology also recommends SGLT2 inhibitor (dapagliflozin or empagliflozin) as additional therapy for HFrEF patients to reduce hospitalization and death risk 17, 18

ARNI Initiation in Hospitalized Heart Failure Patients

Evidence Supporting In-Hospital Initiation

The European Society of Cardiology recommends resolution of acute pulmonary congestion as a criterion for hemodynamic stabilization before initiating sacubitril/valsartan 19
The European Society of Cardiology suggests continuing mineralocorticoid receptor antagonists, such as spironolactone or eplerenone, as cornerstone therapy when initiating sacubitril/valsartan 19

Switching from ARB to Sacubitril/Valsartan in HFrEF

Introduction to Switching

Switching from an ARB to sacubitril/valsartan reduces cardiovascular death and heart failure hospitalization regardless of symptom severity, as recommended by the European Society of Cardiology 20, 21

When to Switch: Clinical Criteria

The American College of Cardiology recommends that all HFrEF patients on ARBs are candidates for switching to sacubitril/valsartan, without needing to wait for patients to "fail" optimal medical therapy first 22, 23
Patients with any NYHA class II-IV symptoms are eligible for switching, even if symptoms are mild 23
Stable clinical status, not actively decompensated, is preferred for switching 23
A systolic BP ≥100 mm Hg is preferred, though lower BP is not an absolute contraindication 22

How to Switch: Practical Algorithm

The American College of Cardiology suggests verifying no contraindications, such as history of angioedema, pregnancy or lactation, severe hepatic impairment, or concomitant ACE inhibitor use, before switching 22
Standard patients should start with 49/51 mg twice daily, while high-risk patients, including those with severe renal impairment (eGFR <30 mL/min/1.73 m²), should start with 24/26 mg twice daily 22, 23
The dose can be doubled every 2-4 weeks as tolerated, with a target dose of 97/103 mg twice daily 22

Managing Common Barriers

Asymptomatic hypotension is not a reason to avoid switching, and sacubitril/valsartan provides mortality benefit even with lower BP 22
If symptomatic hypotension occurs, reducing diuretic dose first or temporarily reducing sacubitril/valsartan dose, then re-titrating, is recommended 22
Mild creatinine elevation (<0.5 mg/dL increase) is acceptable and does not require dose adjustment 22

Evidence Base

The PARADIGM-HF trial demonstrated that sacubitril/valsartan reduced the composite endpoint of cardiovascular death or HF hospitalization by 20% compared to enalapril 23
Meta-analysis of 48 trials with 19,086 participants confirmed mortality benefit (RR 0.86, 95% CI 0.79-0.94) and reduced serious adverse events (RR 0.89, 95% CI 0.86-0.93) 23

Entresto Therapy for Heart Failure with Reduced Ejection Fraction

Patient Selection and Initiation

The European Society of Cardiology recommends Entresto for patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal medical therapy, with benefits occurring regardless of heart failure duration 24
Asymptomatic hypotension should not prevent Entresto initiation or uptitration, as the drug maintains efficacy and safety regardless of baseline blood pressure, even in patients with systolic BP <110 mmHg 25

Dosing and Titration

Patients with systolic BP ≥100 mmHg are preferred candidates, but lower BP is not an absolute contraindication, and monitor closely during initiation and dose titration in patients with borderline blood pressure 25
The American Heart Association suggests targeting the full 97/103 mg twice daily dose for maximum benefit, with dose titration every 2-4 weeks as tolerated 25

Special Populations

Entresto maintains effectiveness in vulnerable populations, including those with signs of congestion, recent heart failure hospitalization, and elderly patients, with benefits occurring within weeks of initiation and independent of age, sex, or background medical therapy 24

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction

Introduction to Sacubitril/Valsartan Therapy

The American Heart Association recommends sacubitril/valsartan as the first-line treatment for patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal therapy with ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, providing a mortality reduction of at least 20% compared to ACE inhibitors 26

Clinical Indications and Patient Population

The European Society of Cardiology recommends sacubitril/valsartan for patients with HFrEF who are symptomatic (NYHA class II-IV) and remain symptomatic despite optimal therapy with ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, with a strength of evidence of Class 1 26

Treatment Strategy and Dosing

The American College of Cardiology recommends initiating sacubitril/valsartan as part of a quadruple therapy regimen, including SGLT2 inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, with a dosing strategy that involves titrating the dose every 2-4 weeks to achieve the target dose of 97/103 mg twice daily 26

Management of Adverse Effects and Contraindications

The European Journal of Heart Failure suggests that asymptomatic hypotension should not preclude the initiation or titration of sacubitril/valsartan, and that benefits are maintained regardless of baseline blood pressure, even with systolic blood pressure <110 mmHg 27

Special Patient Populations

The American Heart Association recommends that patients with heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%) may be considered for sacubitril/valsartan therapy, with a Class 2b recommendation 26
The European Journal of Heart Failure suggests that sacubitril/valsartan can be initiated in hospitalized patients who are stabilized after an acute episode of heart failure, with precautions to maintain systolic blood pressure >100 mmHg during the 6 hours prior to initiation 27

Monitoring Parameters for Entresto (Sacubitril/Valsartan) in HFrEF

Essential Monitoring Parameters

Patients taking Entresto require regular monitoring of blood pressure, renal function, and serum potassium, with particular vigilance during initiation and dose titration, as recommended by the American Heart Association and European Society of Cardiology 28, 29
Monitor serum creatinine and eGFR routinely, especially when used with aldosterone antagonists, to prevent worsening renal function, according to the American College of Cardiology 28
Serial measurement of serum potassium is critical because hyperkalemia may complicate therapy with angiotensin receptor blockers and aldosterone antagonists, as cautioned by the European Heart Journal 28, 29
Caution when serum potassium levels >5.0 mmol/L, particularly when Entresto is combined with mineralocorticoid receptor antagonists, as advised by the European Society of Cardiology 29

Timing of Monitoring

Continue routine monitoring of serum electrolytes and renal function in all patients with heart failure, with frequency adjusted based on clinical status, particularly in patients with impaired renal function or those taking aldosterone antagonists, as recommended by the American Heart Association and European Society of Cardiology 28, 29

Additional Monitoring Considerations

While NT-proBNP levels decrease with Entresto therapy, using BNP measurements to guide dose titration has not been shown to improve outcomes more effectively than achieving target doses proven in clinical trials, according to the American College of Cardiology 28

Sacubitril/Valsartan vs Lisinopril in Dilated Cardiomyopathy

Evidence for Superiority

The American College of Cardiology recommends sacubitril/valsartan over ACE inhibitors for symptomatic HFrEF patients, with evidence supporting replacement strategy and de novo initiation, reducing cardiovascular death or heart failure hospitalization by 20% compared to ACE inhibitors 30

Current Guideline Recommendations

The American College of Cardiology, American Heart Association, and Heart Failure Society of America guidelines recommend sacubitril/valsartan over ACE inhibitors for symptomatic HFrEF patients, with a replacement strategy and de novo initiation supported by evidence 30

Monitoring Requirements

The American College of Cardiology recommends monitoring blood pressure, renal function, and serum potassium at baseline and regularly during titration, with particular vigilance when combined with mineralocorticoid receptor antagonists, and caution when potassium >5.0 mEq/L 30

Initiating Sacubitril/Valsartan in Patients Transitioning from ACE Inhibitors

Pre‑Initiation Eligibility

The American College of Cardiology (ACC) advises that patients should have a systolic blood pressure ≥ 100 mm Hg before starting sacubitril/valsartan; lower values are not an absolute contraindication if the patient is otherwise hemodynamically stable. 31
The ACC recommends an estimated glomerular filtration rate > 30 mL/min/1.73 m² for standard dosing; patients with eGFR ≤ 30 mL/min/1.73 m² have limited trial evidence but may be initiated cautiously at reduced doses. 32
The ACC requires that patients be hemodynamically stable and not volume‑depleted or actively decompensated before transition. 31

Mandatory Washout

The ACC mandates immediate discontinuation of the ACE inhibitor and a 36‑hour washout period before the first dose of sacubitril/valsartan to avoid life‑threatening angioedema. 31

Initial Dosing Strategy

For patients previously on high‑dose ACE inhibitors (equivalent to enalapril ≥ 10 mg daily), the ACC recommends starting sacubitril/valsartan at 49/51 mg twice daily. 31
For patients on low‑to‑medium dose ACE inhibitors (equivalent to enalapril < 10 mg daily), the ACC recommends starting at 24/26 mg twice daily. 31
The ACC suggests the lower starting dose (24/26 mg BID) for special populations: severe renal impairment (eGFR < 30 mL/min/1.73 m²), moderate hepatic impairment (Child‑Pugh B), age ≥ 75 years, or systolic BP 100‑110 mm Hg. 31

Titration Schedule

The ACC advises doubling the dose every 2‑4 weeks as tolerated, aiming for the target dose of 97/103 mg twice daily, which provides the maximal mortality benefit demonstrated in clinical trials. 31

Diuretic Management During Transition

The ACC recommends empirically reducing loop diuretic doses in non‑congested patients at the time of sacubitril/valsartan initiation to mitigate hypotensive effects. 31
The ACC notes that sacubitril/valsartan enhances natriuresis, often allowing a reduction in diuretic requirements, which helps prevent symptomatic hypotension while preserving volume status. 31

Management of Symptomatic Hypotension

For symptomatic hypotension, the ACC first suggests reducing the loop diuretic dose; if hypotension persists, a temporary reduction of sacubitril/valsartan dose is recommended, followed by re‑titration once symptoms resolve. 31

Evidence Base & Guideline Recommendations

The JACC: Heart Failure analysis of the PARADIGM‑HF trial showed that sacubitril/valsartan reduced cardiovascular death or heart‑failure hospitalization by 20 % compared with enalapril in chronic HFrEF patients, with the strongest evidence in NYHA class II (which comprised 70.5 % of the trial population). 32
The ACC (and the European Society of Cardiology) recommends sacubitril/valsartan as a replacement for ACE inhibitors in symptomatic HFrEF patients who are already receiving optimal background therapy. 31
Recent ACC evidence indicates that direct initiation of sacubitril/valsartan without prior ACE‑inhibitor exposure is safe and effective, but when transitioning from an ACE inhibitor, the 36‑hour washout remains mandatory. 31

Evidence‑Based Use of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction

Regulatory Approval and Indications

The United States FDA has approved sacubitril/valsartan for all adults with NYHA class II–IV heart failure and reduced ejection fraction (EF ≤ 40%), independent of baseline blood‑pressure status. This approval is based on pivotal trial data. 33

Patient Eligibility Criteria

Standard dosing is recommended only when the estimated glomerular filtration rate exceeds 30 mL/min/1.73 m². 33
Serum potassium should be below 5.2 mmol/L before initiating therapy to minimize hyper‑kalemia risk. 33
The drug is indicated for patients who are symptomatic (NYHA class II–IV); asymptomatic individuals were not included in the key clinical trials. [33][34]

Clinical Trial Evidence (PARADIGM‑HF)

In the PARADIGM‑HF randomized trial (8,442 participants with chronic HFrEF; 70.1 % NYHA II, 23.9 % NYHA III, 0.7 % NYHA IV), sacubitril/valsartan reduced the composite of cardiovascular death or heart‑failure hospitalization by 20 % compared with enalapril. This result provides Level A evidence (large, multicenter RCT). 33

Guideline Recommendations

The American College of Cardiology (ACC), American Heart Association (AHA), and Heart Failure Society of America (HFSA) give sacubitril/valsartan a Class I, Level B recommendation for patients with HFrEF, reflecting strong consensus based on moderate‑quality evidence. 33